Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Acquisitions & Divestments (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $7.6 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Acquisitions & Divestments fell 70.33% year-over-year to $7.6 million, compared with a TTM value of $109.5 million through Dec 2019, down 0.83%, and an annual FY2024 reading of $143.0 million, up 6.12% over the prior year.
  • Change in Acquisitions & Divestments was $7.6 million for Q4 2019 at Larimar Therapeutics, down from $25.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $59.7 million in Q3 2015 and bottomed at $7.6 million in Q4 2019.
  • Average Change in Acquisitions & Divestments over 5 years is $37.7 million, with a median of $38.3 million recorded in 2017.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 67.98% in 2016, then tumbled 70.33% in 2019.
  • Year by year, Change in Acquisitions & Divestments stood at $56.6 million in 2015, then dropped by 16.5% to $47.2 million in 2016, then fell by 19.45% to $38.0 million in 2017, then crashed by 33.11% to $25.4 million in 2018, then plummeted by 70.33% to $7.6 million in 2019.
  • Business Quant data shows Change in Acquisitions & Divestments for LRMR at $7.6 million in Q4 2019, $25.9 million in Q3 2019, and $41.8 million in Q2 2019.